Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Astrazeneca plc crawled time : 14:30 save search
Electronic Health Records Market size is set to grow by USD 32.27 bn from 2023-2027, benefits of EHR leading to rise in adoption boost the market- Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CCLD | $1.15 0.0% 13K
|
Manufacturing
|
| O: 0.0%
H: 2.99%
C: -2.99%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.55%
H: 0.82%
C: 0.16%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
EVCM | $8.83 1.26% 1.25% 130K
|
Information
|
| O: -0.31%
H: 3.15%
C: 1.68%
GPN | $122.1 -0.07% 0.0% 1.1M
|
Technology Services
|
| O: -0.05%
H: 0.7%
C: 0.54%
DELL | News | $114.87 -2.96% -0.09% 9.4M
|
Electronic Technology
|
| O: -0.66%
H: 1.17%
C: 0.33%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.08%
H: 0.82%
C: 0.67%
health set benefits market
Laboratory Information Management System (LIMS) Market size is set to grow by USD 907.08 mn from 2023-2027, Abbott Laboratories, Computing Solutions, Novatek International and more key players- Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.55%
H: 0.82%
C: 0.16%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.57%
H: 0.98%
C: 0.88%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.08%
H: 0.82%
C: 0.67%
management international system set key market
Vaccine research market size to grow at a CAGR of 9.88% from 2022 to 2027, Abbott Laboratories, Astellas Pharma Inc., AstraZeneca Plc, more to emerge as key players, Technavio
Published: 2024-03-11 (Crawled : 14:30) - prnewswire.com
CMXHF | $172.54 -19.21% 50
|
n/a
|
| O: 0.41%
H: 0.0%
C: 0.0%
CSLLY | $86.918 3.3% 60K
|
n/a
|
| O: -4.92%
H: 3.76%
C: 3.44%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: -3.4%
H: 1.49%
C: 1.49%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.55%
H: 0.82%
C: 0.16%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.6%
H: 0.19%
C: 0.09%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.08%
H: 0.82%
C: 0.67%
pharma vaccine astrazeneca research key market
Anti-rheumatic Market to Grow Exponentially by 2029- Brandessence Market Research
Published: 2023-09-01 (Crawled : 14:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.46%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.07%
H: 3.3%
C: 0.26%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
CPIX | $1.65 6.02% 790
|
Health Technology
|
| O: 0.61%
H: 0.0%
C: 0.0%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.62%
H: 0.26%
C: -0.68%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.86%
H: 0.16%
C: -0.38%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.91%
H: 0.14%
C: -0.76%
research market
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
Published: 2023-08-31 (Crawled : 14:30) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: -1.7%
enhertu her2 granted therapy
Minimal Residual Disease Testing Global Markets and Technology Research Report 2023-2028: Charting Cancer Treatment Trajectories - The Role of MRD Explored
Published: 2023-08-25 (Crawled : 14:30) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -3.27%
H: 3.65%
C: 3.36%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.22%
H: 0.6%
C: 0.31%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.19%
H: 0.25%
C: -0.28%
disease report cancer treatment research global technology
DESTINY-Breast11 Neoadjuvant Phase 3 Trial of ENHERTU® Initiated in Patients with High-Risk HER2 Positive Early-Stage Breast Cancer
Published: 2021-11-30 (Crawled : 14:30) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.7%
H: 0.0%
C: 0.0%
risk trial positive cancer phase 3 breast cancer initiated her2- her2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.